A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects
Psoriasis
About this trial
This is an interventional treatment trial for Psoriasis
Eligibility Criteria
Inclusion Criteria: Healthy male or female subjects between the ages of 18-45 years Have no reproductive potential; or agree to use a highly effective method of contraception, and refrain from donating sperm or eggs during the study period and for at least 6 months after last dosing Have signed the informed consent form approved by the IRB Exclusion Criteria: Have a clinically significant infection currently or within past 30 days, or have a history of active tuberculosis; or have positive screening test for infectious disease, including tuberculosis, viral hepatitis, AIDS and syphilis Have a history of or current allergic disease Have a history of drug or alcohol abuse or currently positive test result(s) for alcohol or drugs of abuse Smokers smoked ≥5 cigarettes per day within past 3 months or have a positive test result for nicotine Clinically significant abnormal physical examination, vital signs, clinical laboratory values, ECGs or imaging tests Pregnant or breastfeeding female subjects Have received hormone-based contraceptives, drugs that prolong the QT interval, drugs that may cause drug interactions with investigational product, immunosuppressants, vaccines or other drugs within a specific period
Sites / Locations
- Huashan Hospital Affiliated to Fudan University
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
HS-10374
Placebo
Single and multiple ascending doses of HS-10374 orally
Single and multiple ascending doses of HS-10374-matched placebo orally